シュレーディンガー Official site

[Live Stream 5/9] Schrödinger Digital Drug Discovery Seminar: Into the Clinic - The Transformation of the Drug Discovery Process Brought by Computational Chemistry - Session 1

シュレーディンガー

Computational chemistry design methods in drug discovery are establishing their presence as one of the essential foundational technologies in the field. Since its founding in 1990, Schrödinger has continuously worked to enhance software and informatics for molecular design, providing practical solutions for pharmaceuticals and chemical materials. By leveraging its own simulation technologies and informatics infrastructure, Schrödinger has demonstrated a track record of efficiently producing high-quality drug designs in numerous drug discovery research projects. This seminar will feature researchers involved in Schrödinger's drug discovery projects presenting real-world examples of computational chemistry in drug discovery. ■ Theme of the First Session Developing potent and selective kinase inhibitors using at-scale FEP and protein FEP: a Wee1 case study ■ Speaker Jennifer Knight, Ph.D., Director, Schrödinger Therapeutics Group *Participation from competing companies is not permitted.